TuHURA Biosciences Completes Asset Acquisition/Disposition

Ticker: HURA · Form: 8-K · Filed: Jun 30, 2025 · CIK: 1498382

Sentiment: neutral

Topics: acquisition, disposition, corporate-action

TL;DR

TuHURA Biosciences filed an 8-K on 6/30/25 for asset acquisition/disposition.

AI Summary

On June 30, 2025, TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K report detailing the completion of an acquisition or disposition of assets. The filing also includes Regulation FD Disclosure and Financial Statements and Exhibits. The company is incorporated in Nevada and its principal executive offices are located in Tampa, Florida.

Why It Matters

This filing indicates a significant corporate action, likely involving the transfer or acquisition of assets, which could impact the company's operational structure and future financial performance.

Risk Assessment

Risk Level: medium — Asset acquisitions or dispositions can introduce significant strategic and financial risks depending on the nature and value of the assets involved.

Key Players & Entities

FAQ

What specific assets were acquired or disposed of by TuHURA Biosciences?

The filing does not specify the exact assets involved in the acquisition or disposition, only that such an event occurred on June 30, 2025.

What was the financial impact of this asset transaction?

The filing indicates the completion of an asset transaction but does not provide specific financial details or the dollar amounts involved in the 8-K itself.

When did TuHURA Biosciences officially change its name from Kintara Therapeutics, Inc.?

The filing lists the date of name change from Kintara Therapeutics, Inc. to TuHURA Biosciences, Inc. as August 20, 2020.

Where are TuHURA Biosciences' principal executive offices located?

TuHURA Biosciences' principal executive offices are located at 10500 University Center Dr., Suite 110, Tampa, Florida 33612.

What is the SIC code for TuHURA Biosciences?

The Standard Industrial Classification (SIC) code for TuHURA Biosciences is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 30, 2025 regarding TuHURA Biosciences, Inc./NV (HURA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing